Cancer screening rates in individuals with different life expectancies

JAMA Internal Medicine

Volumn 174, Issue 10, 2014, Pages 1558-1565

  Royce, Trevor J ^a,b   Hendrix, Laura H ^a   Stokes, William A ^a,b   Allen, Ian A ^a,b   Chen, Ronald C ^a,c  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; COLORECTAL CANCER; FEMALE; HUMAN; HYSTERECTOMY; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PAPANICOLAOU TEST; PROSTATE CANCER; SENSITIVITY ANALYSIS; UNITED STATES; UTERINE CERVIX CANCER; BLOOD; BREAST NEOPLASMS; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; EPIDEMIOLOGY; EVIDENCE BASED MEDICINE; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; MORTALITY; NEOPLASMS; PROCEDURES; PROSTATIC NEOPLASMS; RISK; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UNNECESSARY PROCEDURE; UTERINE CERVICAL NEOPLASMS;

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; BREAST NEOPLASMS; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; LIFE EXPECTANCY; LOGISTIC MODELS; MALE; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; NEOPLASMS; PAPANICOLAOU TEST; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; UNNECESSARY PROCEDURES; UTERINE CERVICAL NEOPLASMS;

EID: 84907991779     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.3895     Document Type: Article

References (44)

1. Koh HK. A 2020 vision for healthy people. N Engl J Med. 2010;362(18):1653-1656.
2. US Department of Health and Human Services. Healthy People. http://www.healthypeople.gov. Accessed June 27, 2012.
3. Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA. 2001;285(21):2750-2756.
4. Woolf SH, Harris R. The harms of screening: new attention to an old concern. JAMA. 2012;307(6): 565-566.
5. Schnipper LE, Lyman GH, Blayney DW, et al. American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol. 2013;31(34):4362-4370.
6. Wolf AM, Wender RC, Etzioni RB, et al; American Cancer Society Prostate Cancer Advisory Committee. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60(2):70-98.
7. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA Guideline. J Urol. 2013;190(2):419-426.
8. Qaseem A, Denberg TD, Hopkins RH Jr, et al; Clinical Guidelines Committee of the American College of Physicians. Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann Intern Med. 2012;156(5):378-386.
9. Lee CH, Dershaw DD, Kopans D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol. 2010;7(1):18-27.
10. Moyer VA; U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;156(12):880-891, W312.
11. Saslow D, Solomon D, Lawson HW, et al; ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147-172.
12. US Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151(10):716-726, W-236.
13. Tonelli M, Connor Gorber S, Joffres M, et al; Canadian Task Force on Preventive Health Care. Recommendations on screening for breast cancer in average-risk women aged 40-74 years. CMAJ. 2011;183(17):1991-2001.
14. U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149(9):627-637.
15. Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-134.
16. Design and estimation for the National Health Interview Survey, 1995-2004. Vital Health Stat 2. 2000;(130):1-31.
17. Adams PE, Martinez ME, Vickerie JL, Kirzinger WK. Summary health statistics for the U.S. population: National Health Interview Survey, 2010. Vital Health Stat 10. 2011;(251):1-117.
18. Zwerling C, Whitten PS, Davis CS, Sprince NL. Occupational injuries among workers with disabilities: the National Health Interview Survey, 1985-1994. JAMA. 1997;278(24):2163-2166.
19. NCHS. Sample SAS statements: create "time since cancer screening test" recodes. http://www.cdc.gov/NCHS/nhis/nhis-2008-data-release.htm. Accessed May 9, 2012.
20. Bandi P, Cokkinides V, Smith RA, Jemal A. Trends in colorectal cancer screening with home-based fecal occult blood tests in adults ages 50 to 64 years, 2000-2008. Cancer. 2012;118(20): 5092-5099.
21. Centers for Disease Control and Prevention (CDC). Cancer screening-United States, 2010. MMWR Morb Mortal Wkly Rep. 2012;61(3):41-45.
22. Rauscher GH, Johnson TP, Cho YI, Walk JA. Accuracy of self-reported cancer-screening histories: ameta-analysis. Cancer Epidemiol Biomarkers Prev. 2008;17(4):748-757.
23. Schonberg MA, Davis RB, McCarthy EP, Marcantonio ER. External validation of an index to predict up to 9-year mortality of community-dwelling adults aged 65 and older. J Am Geriatr Soc. 2011;59 (8):1444-1451.
24. Schonberg MA, Davis RB, McCarthy EP, Marcantonio ER. Index to predict 5-year mortality of community-dwelling adults aged 65 and older using data from the National Health Interview Survey. J Gen Intern Med. 2009;24(10):1115-1122.
25. Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA. 2006;296(19):2336-2342.
26. Prasad SM, Drazer MW, Huo D, Hu JC, Eggener SE. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA. 2012;307(16):1692-1694.
27. Bellizzi KM, Breslau ES, Burness A, Waldron W. Prevalence of cancer screening in older, racially diverse adults: still screening after all these years. Arch Intern Med. 2011;171(22):2031-2037.
28. Walter LC. What is the right cancer screening rate for older adults. Arch Intern Med. 2011;171(22): 2037-2039.
29. Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2013;158 (10):761-769.
30. Sirovich BE, Welch HG. Cervical cancer screening among women without a cervix. JAMA. 2004;291(24):2990-2993.
31. Pollack CE, Platz EA, Bhavsar NA, et al. Primary care providers' perspectives on discontinuing prostate cancer screening. Cancer. 2012;118(22): 5518-5524.
32. Yourman LC, Lee SJ, Schonberg MA, Widera EW, Smith AK. Prognostic indices for older adults: a systematic review. JAMA. 2012;307(2):182-192.
33. Merenstein D. A piece of my mind: winners and losers. JAMA. 2004;291(1):15-16.
34. Hurwitz B. How does evidence based guidance influence determinations of medical negligence? BMJ. 2004;329(7473):1024-1028.
35. Steurer J, Held U, Schmidt M, Gigerenzer G, Tag B, Bachmann LM. Legal concerns trigger prostate-specific antigen testing. J Eval Clin Pract. 2009;15(2):390-392.
36. Sima CS, Panageas KS, Schrag D. Cancer screening among patients with advanced cancer. JAMA. 2010;304(14):1584-1591.
37. Berwick DM, Hackbarth AD. Eliminating waste in US health care. JAMA. 2012;307(14):1513-1516.
38. Heijnsdijk EA, der Kinderen A, Wever EM, Draisma G, Roobol MJ, de Koning HJ. Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer. 2009;101(11):1833-1838.
39. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013;1:CD004720.
40. Shteynshlyuger A, Andriole GL. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer. J Urol. 2011;185(3):828-832.
41. Jacobs BL, Zhang Y, Schroeck FR, et al. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA. 2013; 309(24):2587-2595.
42. Zappa M, Visioli CB, Ciatto S. Mammography screening in elderly women: efficacy and cost-effectiveness. Crit Rev Oncol Hematol. 2003; 46(3):235-239.
43. Woloshin S, Schwartz LM. The benefits and harms of mammography screening: understanding the trade-offs. JAMA. 2010;303(2):164-165.
44. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA. 2009;302(15):1685-1692.